BACKGROUND: Concern regarding recurrence of pre-transplant (Tx) malignancy has disqualified patients from Tx. Because this has been poorly studied in lung and heart Tx recipients our aim was to investigate the influence of pre-Tx malignancy on post-Tx recurrence and long-term survival, focusing on pre-operative cancer-free intervals. METHODS: From our lung and heart Tx programs (1983 to 2011) we retrospectively identified 111 (lung, 37; heart, 74) of 3,830 recipients with 113 pre-Tx malignancies. The patients were divided into 3 groups by pre-Tx cancer-free interval: Group I, = 12 to = 60 months (n = 71). RESULTS: Mean age at pre-Tx malignancy was 35 +/- 18 years. Mean post-Tx follow-up time was 70 +/- 63 months (range, 0-278 months), and m...
SummaryBackgroundIn the era of improving overall survival rates of malignant diseases, the impact of...
BackgroundLung cancer may occur in the lung transplant population because many patients are former s...
OBJECTIVES: Mandatory use of prolonged immunosuppression in organ transplantation is complicated by ...
BACKGROUND: Malignancy is a concern in cardiac transplant recipients, but the temporal trends of de ...
Background: Heart transplantation and malignancy connect in several ways. Cancer can be an incidenta...
Long-term survival after heart transplantation (HTX) is impacted by adverse effects of immunosuppres...
WOS: 000269540900029PubMed ID: 19486222Background: Malignancy is an important complication after hea...
Background: Malignancy is generally considered a contraindication for cardiac transplantation, where...
[Abstract] Neoplasm history increases morbidity and mortality after solid organ transplantation and ...
Purpose: Recent history of malignancy without 5-year disease-free interval is an absolute contraindi...
Objective. Chronic immunosuppressive therapy following solid organ transplantation has been correlat...
The prevalence of different cancers after heart transplant (HT) is unclear due to small and conflict...
BackgroundThe purpose of this study was to assess the incidence and type of malignancies after heart...
Aim: Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and liver ...
Neoplasm history increases morbidity and mortality after solid organ transplantation and has disqual...
SummaryBackgroundIn the era of improving overall survival rates of malignant diseases, the impact of...
BackgroundLung cancer may occur in the lung transplant population because many patients are former s...
OBJECTIVES: Mandatory use of prolonged immunosuppression in organ transplantation is complicated by ...
BACKGROUND: Malignancy is a concern in cardiac transplant recipients, but the temporal trends of de ...
Background: Heart transplantation and malignancy connect in several ways. Cancer can be an incidenta...
Long-term survival after heart transplantation (HTX) is impacted by adverse effects of immunosuppres...
WOS: 000269540900029PubMed ID: 19486222Background: Malignancy is an important complication after hea...
Background: Malignancy is generally considered a contraindication for cardiac transplantation, where...
[Abstract] Neoplasm history increases morbidity and mortality after solid organ transplantation and ...
Purpose: Recent history of malignancy without 5-year disease-free interval is an absolute contraindi...
Objective. Chronic immunosuppressive therapy following solid organ transplantation has been correlat...
The prevalence of different cancers after heart transplant (HT) is unclear due to small and conflict...
BackgroundThe purpose of this study was to assess the incidence and type of malignancies after heart...
Aim: Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and liver ...
Neoplasm history increases morbidity and mortality after solid organ transplantation and has disqual...
SummaryBackgroundIn the era of improving overall survival rates of malignant diseases, the impact of...
BackgroundLung cancer may occur in the lung transplant population because many patients are former s...
OBJECTIVES: Mandatory use of prolonged immunosuppression in organ transplantation is complicated by ...